Picture of ASP Isotopes logo

ASPI ASP Isotopes Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Momentum

Relative Strength (%)
1m+42.02%
3m+50%
6m+137.74%
1yr+25.1%
Volume Change (%)
10d/3m+20.91%
Price vs... (%)
52w High-11.8%
50d MA+29.4%
200d MA+124.37%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)40.57
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value16.03
Price to Tang. Book16.03
Price to Free Cashflown/a
Price to Salesn/a
EV to EBITDAn/a

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-145.53%
Return on Equity-179.55%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of ASP Isotopes EPS forecast chart

Profile Summary

ASP Isotopes Inc. is a pre-commercial stage advanced materials company. The Company has a license to use technology, the Aerodynamic Separation Process (ASP technology), originally developed and licensed to it by Klydon Proprietary Ltd (Klydon), for the production, distribution, marketing and sale of all isotopes. Its initial focus is on the production and commercialization of enriched Carbon-14 (C-14), Molybdenum-100 (Mo-100) and Silicon-28 (Si-28). It also intends to develop the ASP technology to produce enriched Uranium-235 (U-235). It operates principally through subsidiaries: ASP Isotopes Guernsey Limited, which is focused on the development and commercialization of high value, low volume isotopes for highly specialized end markets; Enriched Energy LLC, which is focused on the development and commercialization of uranium for the nuclear energy market, and ASP Isotopes UK Ltd, which is the licensee of the ASP technology under the license agreement with Klydon.

Directors

    Last Annual
    December 31st, 2022
    Last Interim
    September 30th, 2023
    Incorporated
    September 13th, 2021
    Public Since
    November 10th, 2022
    No. of Employees
    46
    Sector
    Pharmaceuticals
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Capital Market
    Shares in Issue
    48,773,276

    ASPI Share Price Performance

    Similar to ASPI

    Picture of 60 Degrees Pharmaceuticals logo

    60 Degrees Pharmaceuticals

    us flag iconNASDAQ Capital Market

    Picture of Aadi Bioscience logo

    Aadi Bioscience

    us flag iconNASDAQ Capital Market

    Picture of Acasti Pharma logo

    Acasti Pharma

    us flag iconNASDAQ Capital Market

    Picture of Affinia Therapeutics logo

    Affinia Therapeutics

    us flag iconNASDAQ Capital Market

    Picture of Agriforce Growing Systems logo

    Agriforce Growing Systems

    us flag iconNASDAQ Capital Market

    FAQ